@DrMakaryFDA As Dr. Makary noted on real-world evidence, citing ANKTIVA as an example is entirely appropriate. Approve it now—countless cancer patients desperately await this life-saving breakthrough. @DrPatrick $IBRX
The world bank of natural killer cells is close. Data from production of billions of NK cells and successful cryopreservation from pver 60 healthy volunteers and cancer patients coming soon. The Leonardo AI driven robot will transform the availability of NK cells globally.
Gavin Newsom rejects bill to phase out “forever” chemicals used in cookware, children’s products. Nuts. Politics over health!!! PFAS is a toxic cancer causing chemical. https://t.co/0fJ1wcIcte
Ask your doctor: “ what is my ALC?”and the reaction may be interesting . Next ask “what is my NLR ratio”?
Trying very hard to discuss this important science to evolve our thinking of how to treat our patients with cancer. Publication on lung cancer and 10 tumor types submitted.
The failed RAPIDO trial highlights the point that more chemo- radiation harms the immune system even further. For decades we still pursue this path without realizing that the ALC count , a simple measure of NK and T cells are decreased by this therapy. So little wonder that it does not work. NO NK CELLS AND NO T-CELLS NO TUMOR CELL DEATH. Pretty simple!!
6 years ago with President Michael Crow from ASU. Batman he calls me! But sadly very little has changed. We know more today since that interview. Cancer killer cells can be activated across all tumor types. So badly need to catalyze movement for better care.
Neuralink Integration with ANKTIVA for Revolutionary Immunotherapy
@elonmusk, a visionary collaboration opportunity by Dr. Sarabi and Grok.
Dear Mr Musk:
Good morning sir! I would like to bring to your attention the remarkable work of Dr. Patrick Soon-Shiong, who has developed a groundbreaking therapy, Anktiva, capable of supercharging key immune molecules to combat cancer and COVID-19.
In a recent discussion with Tucker Carlson, Dr. Soon-Shiong described this advance as akin to the “E=mc²” of medicine—the discovery of “God’s equation,” a biological key that has eluded us for half a century until now.
Just as Tesla has revolutionized the automotive and environmental industries, and SpaceX has advanced the expansion of humanity into a multi-planetary species to ensure our long-term survival, Anktiva represents a comparable paradigm shift in medicine, safeguarding human health and endurance.
Given your shared commitment to advancing humanity, I respectfully inquire whether you might consider extending your support to Dr. Soon-Shiong in this critical pursuit. Moreover, I propose exploring the integration of Neuralink, employing the stepwise protocol outlined below, in collaboration with Dr. Soon-Shiong. Such a partnership could propel an unprecedented advancement in medicine and the future of humankind.
Grok has developed a preliminary conceptual integration of Neuralink to enhance and supercharge IL-15 production
1/7: Identify Target Neural Circuits
• Map the hypothalamic paraventricular nucleus (PVN) and dorsal motor nucleus of the vagus
• Trace efferent projections from the PVN to the intermediolateral cell column (IML) in the spinal cord.
• Identify sympathetic nerve fibers innervating the spleen and lymph nodes.
• Map vagus nerve branches terminating in gut-associated lymphoid tissue and the hepatic portal system.
2/7: Implant Neuralink and Integrate with Neural Pathways
• Place Neuralink electrodes in the PVN and dorsal motor nucleus of the vagus, using extended threads for subcortical/brainstem access.
• Configure for recording/stimulation to modulate autonomic outflow to the IML at thoracic spinal levels.
• Establish central control over peripheral pathways (e.g., splenic/vagus nerves) via targeted brain stimulation.
3/7: Develop Stimulation Protocols
• Program Neuralink for high-frequency stimulation to the PVN for sympathetic activation.
• Apply low-frequency patterned stimulation to the dorsal motor nucleus to engage feedback loops.
• Modulate splenic/vagal pathways with phase-locked cycles through central interfaces.
4/7: Initiate Immune Cell Activation
• Stimulate pathways to induce IFN-γ and TNF-α release in spleen/lymph nodes.
• Trigger IL-15 transcription/translation in dendritic cells, monocytes, and epithelial cells.
• Monitor for increased membrane-bound IL-15/IL-15Rα complex formation.
5/7: Enhance Local IL-15 Presentation
• Concentrate stimulation at tumor/inflammation sites.
• Promote immune cell clustering via chemokine/adhesion molecule induction.
• Sustain localized IL-15/IL-15Rα trans-presentation to NK and CD8+ T cells.
6/7: Implement Real-Time Monitoring and Feedback
• Record neural/immune biomarkers continuously via Neuralink telemetry.
• Adjust stimulation based on IL-15 levels and NK/T cell activity.
• Set safety thresholds to avoid excessive immune activation.
7/7: Synchronize with Immunotherapy
• Time stimulation with IL-15 superagonists or adoptive therapies.
• Evaluate synergies using immune monitoring/imaging.
• Optimize based on patient responses.
Thank you!
#Neuralink #ANKTIVA #Grok
#trendingvideo #cancer #medicalnews #health #trendingnow